Recorded Webinar from January, 2021
In this webinar, we will discuss how advances in bioanalytical assays and technologies have improved immunoassay performance, closing the gap in assay drawbacks for cell and gene therapy manufacturing.
Examples from Gyrolab® microfluidic, CD-based immunoassay platform will be presented demonstrating AAV titer, LV titer, and bioprocessing HEK 293 host cell protein impurity analysis improvements.
Through the panel discussion, attendees will learn about:
Director of Service and Scientific Support
Gyros Protein Technologies
Director of Bioanalysis
Freeline Therapeutics Ltd
Senior Scientific Fellow, Exploratory Analytical Development and Validation
Adverum Biotechnologies, Inc.
If you have problems to view the webinar please contact email@example.com